Chemotherapy News and Research

Latest Chemotherapy News and Research

Natural formula can fight against highly invasive breast cancer

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.

19 Jul 2011

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Aeterna Zentaris Inc. today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology, to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

19 Jul 2011

HER2-positive metastatic breast cancer women benefit from trastuzumab and chemotherapy

The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

18 Jul 2011

Cancer rates increase among middle-aged people in Great Britain

CANCER rates in middle-aged men and women in Great Britain have gone up by nearly 20 per cent in a generation - an increase of 17,000 cases a year - according to new figures released today (Monday) by Cancer Research UK.

18 Jul 2011

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

Seattle Genetics, Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10-0 to recommend that the FDA grant accelerated approval of ADCETRIS™ (brentuximab vedotin) for the treatment of patients with Hodgkin lymphoma who relapse after autologous stem cell transplant (ASCT).

15 Jul 2011

Novel combined technique for treating neoplastic meningitis, hydrocephalus

Approximately five to ten percent of patients with primary or metastatic cancer suffer from devastating neurological complications such as headaches, seizures, confusion, difficulty swallowing and visual disturbances. These deficits are caused by a life-threatening form of brain invasion from cancer called neoplastic meningitis.

15 Jul 2011

Study: Bone marrow transplant offers new hope for patients with high-risk leukemia

Bone marrow transplant survival more than doubled in recent years for young, high-risk leukemia patients treated at St. Jude Children's Research Hospital, with patients who lacked genetically matched donors recording the most significant gains. The results are believed to be the best ever reported for leukemia patients who underwent bone marrow transplantation.

15 Jul 2011

Seattle Children's inaugurates new center for cancer research

Today, Seattle Children's Research Institute announced the opening of the Center for Childhood Cancer Research.

15 Jul 2011

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

15 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

Seattle Genetics lymphoma drug gets FDA panel nod

Seattle Genetics Inc. has finally obtained the U.S. Food and Drugs Administration (FDA) nod for a second type of blood cancer drug. The FDA advisory committee voted 10-0 on Thursday to recommend accelerated approval of the drug, under the proposed trade name Adcetris, for anaplastic large cell lymphoma (ALCL). The panel earlier unanimously approved the drug for Hodgkin's lymphoma, another type of blood cancer.

14 Jul 2011

Scientists discover new mechanism of drug resistance in hospital microbes

Hospitals struggle to prevent the infections that complicate treatment for cancer, joint replacement, heart surgery and other conditions. Hospital-acquired infections are often resistant to multiple antibiotics, leading to approximately 100,000 deaths and more than $30 billion in additional health care costs yearly.

14 Jul 2011

Progesterone could fight against neuroblastoma

High doses of the hormone progesterone can kill neuroblastoma cells while leaving healthy cells unscathed, scientists at Emory University School of Medicine have found in laboratory research.

14 Jul 2011

ASLAN, Array sign license agreement to develop ARRY-543 for solid tumors

ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc. today announced a license agreement to develop Array's HER2 / EGFR inhibitor, ARRY-543, currently entering Phase 2 development for solid tumors.

14 Jul 2011

U.S. Senators introduce Pulmonary Fibrosis Research Enhancement Act

The Coalition for Pulmonary Fibrosis (CPF) announced today the Pulmonary Fibrosis Research Enhancement Act has been introduced in the Senate by Senators Chris Coons and Mike Crapo in the U.S. House of Representatives by Rep. Erik Paulsen and Rep. Tammy Baldwin.

13 Jul 2011

U.S. hospitals report severe drug shortages: Survey

A survey called “Impact of Drug Shortages on U.S. Health Systems” released this Tuesday showed that a vast majority of U.S. hospitals have restricted the use of life-saving chemotherapy drugs and other critical-care medications in the past six months to cope with unprecedented shortages.

13 Jul 2011

Blood cancer drug trial results questioned by FDA

U.S. drug reviewers might limit the use of a Seattle Genetics Inc’s experimental blood cancer drug due to the narrow scope of its clinical trials. According to papers released Tuesday by the Food and Drug Administration (FDA), it requests an advisory panel to consider the drug, under the proposed trade name Adcetris known chemically as brentuximab vedotin, for use in previously treated patients with Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL).

13 Jul 2011

New insights into how cancer cells can maintain resistance to chemotherapy

Researchers from the Royal College of Surgeons in Ireland (RCSI) have conducted a study which reveals new insights into how cancer cells can maintain a resistance to chemotherapy resulting in cancer relapse.

12 Jul 2011

New method allows for concurrent treatment of spinal tumors and stabilization of the spine

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz has recently deployed a new system for the treatment of spinal tumors for the first time.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011